EFFICACY OF CHECKPOINT INHIBITOR IMMUNOTHERAPY DRUG PEMBROLIZUMAB (KEYTRUDA) FOR TREATMENT OF ADVANCED CERVICAL CANCER

被引：0
|
作者：
Ahmed, F. [1 ]
Shah, Z. [2 ]
Khan, I. [1 ]
Bhatnagar, A. [1 ]
Garimella, R. [1 ]
Mishra, S. [1 ]
Gudapati, S. [3 ]
Bobba, S. H. [3 ]
Zaidi, S. [4 ]
Andrews, K. [5 ]
Salman, U. [6 ]
Yukselen, Z. [1 ]
Guntipalli, P. [1 ]
Zarrar, R. [7 ]
Nya, G. Enebong [8 ]
Ahmad, S. [9 ]
机构：
[1] Larkin Community Hosp, Div Clin & Translat Res, South Miami, FL USA
[2] Weiss Mem Hosp, Dept Internal Med, Chicago, IL USA
[3] Washington Univ Hlth & Sci, Coll Med, San Pedro, Belize
[4] Lahore Med & Dent Coll, Coll Med, Lahore, Pakistan
[5] Prince Mohammad Bin Fahad Univ, Dept CORE, Al Khobar, Saudi Arabia
[6] Bakhtawar Amin Med & Dent Coll, Coll Med, Multan, Pakistan
[7] Mayo Clin, Dept Oncol, Rochester, MN USA
[8] Johns Hopkins Univ Hosp, Dept Gynecol Oncol, Baltimore, MD USA
[9] Advent Hlth Canc Inst, Div Gynecol Oncol, Orlando, FL USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2021年 / 31卷
关键词：
D O I：
10.1136/ijgc-2021-ESGO.43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
567
引用
收藏
页码：A32 / A32
页数：1
相关论文
共 50 条
  • [41] Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer
    Yi, Xue-Mei
    Cai, Hong-Qiao
    Jiao, Yan
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2025, 17 (02):
  • [42] Efficacy of MERTK inhibitor in combination with pembrolizumab in lung cancer
    Pyo, Kyoung-Ho
    Cho, Ha-Ni
    Xin, Chun-Feng
    Cho, Jae Seok
    Kang, Han Na
    Yun, Jiyeon
    Kim, Hye Ryun
    Cho, Byoung Chul
    CANCER RESEARCH, 2019, 79 (13)
  • [43] Effect of antibiotic treatment on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer
    Alkan, G.
    Oztas, N. Senturk
    Turna, Z. H.
    Ozguroglu, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1082 - S1082
  • [44] Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer
    Gatti-Mays, Margaret E.
    Gameiro, Sofia R.
    Ozawa, Yohei
    Knudson, Karin M.
    Hicks, Kristin C.
    Palena, Claudia
    Cordes, Lisa M.
    Steinberg, Seth M.
    Francis, Deneise
    Karzai, Fatima
    Lipkowitz, Stanley
    Donahue, Renee N.
    Jochems, Caroline
    Schlom, Jeffrey
    Gulley, James L.
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [45] Clinical efficacy and safety of cadonilimab immunotherapy in patients with advanced cervical cancer: A retrospective study
    Han, Xiuchen
    Tan, Huaming
    Fang, Minjie
    Wang, Minjie
    Zhou, Yayan
    Sheng, Xiugui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy
    Yang, Ying
    Meng, Wen-Jian
    Wang, Zi-Qiang
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2023, 28 (04):
  • [47] Biomarkers of immune checkpoint inhibitor efficacy in cancer
    Meyers, D. E.
    Banerji, S.
    CURRENT ONCOLOGY, 2020, 27 : S106 - S114
  • [48] Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma
    Hung, Hao-Chien
    Lee, Jin-Chiao
    Wang, Yu-Chao
    Cheng, Chih-Hsien
    Wu, Tsung-Han
    Lee, Chen-Fang
    Wu, Ting-Jung
    Chou, Hong-Shiue
    Chan, Kun-Ming
    Lee, Wei-Chen
    CANCERS, 2021, 13 (07)
  • [49] Pembrolizumab (KEYTRUDA®) in Combination with Axitinib (Inlyta®) for First-line Treatment of advanced Renal Cell Cancer Death Risk under Pembrolizumab Combination is almost halved Compared to Sunitinib
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (04) : 233 - 233
  • [50] Cervical cancer-immunotherapy in locally advanced and metastatic cervical cancer: status quo and new treatment options
    Schubert, M.
    Bauerschlag, D. O.
    Alkatout, I.
    ONKOLOGIE, 2025, 31 (01): : 104 - 109
12345